KentGRobersonMD

Family Medicine • Colorado Springs, CO

Complementary and Integrative Medicine

Medical Director of Family Health Center

Join to view full profile

Dr. Roberson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Roberson's full profile

Already have an account?

Office
6547 North Academy
#212
Colorado Springs, CO 80918
Phone+1 719-299-7696

Fax+1 719-299-7696

Clinical Expertise

Travel and tropical medicine

Education & Training

In His Image at St John Medical CenterResidency, Family Medicine, 1992 - 1995
University of Wisconsin School of Medicine & Public HealthClass of 1992

Certifications & Licensure

CO State Medical License 1995 - 2025
OK State Medical License 1993 - 2000
National Board of Physicians and Surgeons Family Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy Start of enrollment: 2005 Sep 01
Completed
Phase 3
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy Start of enrollment: 2005 Dec 01
Completed
Phase 3
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension Start of enrollment: 2007 Dec 01
Completed
Phase 3
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension. Start of enrollment: 2008 Apr 01
Completed
Phase 3
A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150) Start of enrollment: 2008 Oct 01
Completed
Phase 3
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia Start of enrollment: 2009 May 01
Completed
Phase 3
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia Start of enrollment: 2009 May 01
Completed
Phase 3
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Start of enrollment: 2010 Apr 23
Completed
Phase 3
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). Start of enrollment: 2010 Jul 01
Completed
Phase 3
LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Start of enrollment: 2010 Nov 01
Completed
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Start of enrollment: 2011 Aug 01
Completed
Phase 3
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia Start of enrollment: 2015 Feb 04
Completed
Phase 3
Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects Start of enrollment: 2014 Dec 11
Completed
Phase 2
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease Start of enrollment: 2015 Jun 26
Completed
Phase 3
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine Start of enrollment: 2015 Sep 01
Completed
Phase 3
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) Start of enrollment: 2016 Sep 26
Completed
Phase 2, Phase 3
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Start of enrollment: 2016 Jul 22
Completed
Phase 3
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Start of enrollment: 2016 Sep 13
Completed
Phase 3
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease Start of enrollment: 2016 Dec 14
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH) Start of enrollment: 2017 Jan 19
Terminated
Phase 3
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH) Start of enrollment: 2017 Jan 17
Terminated
Phase 3
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Start of enrollment: 2017 Jan 31
Active, not recruiting
Phase 3
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs Start of enrollment: 2017 Mar 13
Completed
Phase 3
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache Start of enrollment: 2017 Apr 27
Terminated
Phase 3
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine Start of enrollment: 2017 Oct 13
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

27 citations
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan...
David Fitz-Patrick, Kent Roberson, Kiyoshi Niwa, Takabumi Fujimura, Koji Mori
Modern Rheumatology. 2019-11-01

Research History

Principal Investigator2005 - 2020

Industry Relationships

Principle Investigator, Delta WavesPrincipal Investigator for research Studies2006 - 2020